U.S. President Donald Trump said on Tuesday he intends to impose a "25% or higher" levies on semiconductors and ...

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per ...

U.S. President Donald Trump plans to impose 25% or higher tariffs on semiconductors and pharmaceutical imports, increasing ...

U.S. President Donald Trump said on Tuesday he intends to impose a "25% or higher" levies on semiconductors and ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.

For investors eyeing Biocon’s stock, this approval could be a significant catalyst. According to InvestingPro’s fair value ...

Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be ...